Cite
HARVARD Citation
Lynch, S. et al. (n.d.). Baseline characteristics for CLARITY AD: A phase 3 placebo‐controlled, double‐blind, parallel‐group, 18‐month study evaluating lecanemab (ban2401) in early Alzheimer's disease. Alzheimer's & dementia. p. n/a. [Online].